Pure Global
NCT06090123

Drug-Drug Interaction (DDI) Study for TPN171H

A Phase 1,Parallel Assignment,Fixed-Sequence Study to Assess the Effect of Itraconazole, Rifampicin on the Pharmacokinetics of TPN171H in Healthy Subjects
Vigonvita Life Sciences·Phase 1·ClinicalTrials.gov·drugCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Erectile Dysfunction
Drug/Device/Intervention
TPN171H
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Vigonvita Life Sciences
Location
Shanghai, China
Timeline & enrollment
Phase
Phase 1
Start date
Jan 01, 2020
End date
Sep 02, 2020
Enrollment
24 participants
Primary outcome

Cmax of TPN171H,AUC of TPN171H

Summary

The primary objective of this study was to assess the effect of rifampicin,a cytochrome P450
 3A4 enzyme (CYP3A4) induction, on the pharmacokinetics (PK) of TPN171H in chinese healthy
 male subjects ,and assess the effect of itraconazole，cytochrome P450 3A4 enzyme (CYP3A4)
 induction on the PK of TPN171H in chinese healthy male subjects

ICD-10 classifications
Orgasmic dysfunctionOther disorders of penisOther specified disorders of penisSexual dysfunction, not caused by organic disorder or diseaseTesticular dysfunction
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06090123
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06090123 through Pure Global AI's free database. This Phase 1 trial is sponsored by Vigonvita Life Sciences and is currently Completed. The study focuses on Erectile Dysfunction. Target enrollment is 24 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.